1146956-44-6Relevant articles and documents
SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF
-
, (2020/08/22)
A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labe
CANCER DIAGNOSTIC IMAGING AGENTS
-
, (2020/08/22)
The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.
Para-functionalized aryl-di-tert-butylfluorosilanes as potential labeling synthons for18F radiopharmaceuticals
Iovkova, Ljuba,Waengler, Bjoern,Schirrmacher, Esther,Schirrmacher, Ralf,Quandt, Gabriele,Boening, Guido,Schuermann, Markus,Jurkschat, Klaus
experimental part, p. 2140 - 2147 (2009/10/01)
The syntheses of the functionalized triorganofluorosilanes tBu 2-(P-XC6H4)SiF (3 a, X = SH; 4 a, X = NCS; 4b, X = NCO; 5, X = NC4H2O2; 7, X = COOH; 8 a, X = COONC4H4O